Clinical Trials
10 trialsNCT07270835 2025-12-08
Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma
The First Affiliated Hospital of Soochow University
Phase 4 Recruiting
NCT03229200 2025-10-30
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
Pharmacyclics Switzerland GmbH
Phase 4 Active not recruiting
NCT06956092 2025-05-02
Glofitamab
Zhengzhou University
Phase 4 Not yet recruiting
NCT05806580 2024-10-23
Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma
Ruijin Hospital
Phase 4 Recruiting
NCT06609304 2024-10-15
axi-cel
Zhengzhou University
Phase 4 Recruiting
NCT05814848 2023-06-15
A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma
Changhai Hospital
Phase 4 Not yet recruiting
NCT01990534 2021-04-09
A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma
Takeda
Phase 4 Completed
NCT04152577 2019-11-05
R2 and Combination Chemotherapy Versus R and Combination Chemotherapy in Newly Diagnosed Highly Aggressive B-NHL
Shandong Provincial Hospital
Phase 4 Unknown
NCT02996617 2016-12-19
PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia
Shandong Provincial Hospital
Phase 4 Unknown
NCT02992834 2016-12-14
Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma
The First People's Hospital of Changzhou
Phase 4 Unknown